Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neuroendocrine Tumors 11Gastro-enteropancreatic neuroendocrine tumor 2Pheochromocytoma 1Paraganglioma 1Meningioma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma 1Carcinoid Tumor 1Advanced Neuroendocrine Neoplasm 1Adenoma, Islet Cell 1

Interventions

atezolizumab 2lutetium Lu 177 dotatate 1Etoposide 1EC regimen 1Drug Therapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Extensive Stage Small Cell Lung Cancer × lutetium Lu 177 dotatate × Clear all
NCT05142696 2026-05-29

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Novartis

Phase 1/2 Active not recruiting
24 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡